INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Components of income tax expense (benefit) continuing operations [Line Items]
Valuation Allowances and Reserves, Period Increase (Decrease)	$ (59,352,000)
Components of income (loss) before income taxes [Abstract]
United States	57,258,000	20,069,000	3,729,000
Foreign	(18,250,000)	(5,201,000)	(1,288,000)
INCOME BEFORE INCOME TAXES	39,008,000	14,868,000	2,441,000
Current income tax benefit (expense):
Federal	226,000	(225,000)	0
State	0	0	2,660,000
Foreign	(6,600,000)	(4,994,000)	(1,946,000)
Current income tax benefit (expense)	(6,374,000)	(5,219,000)	714,000
Deferred income tax (expense) benefit:
Federal	(16,811,000)	0	0
State	(1,192,000)	0	0
Foreign	69,000	11,000	0
Deferred income tax expense, gross	(17,934,000)	11,000	0
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	59,352,000	0	0
Income tax benefit (expense)	35,044,000	(5,208,000)	714,000
Reconciliation of the statutory U.S. federal tax rate to the effective tax rate [Abstract]
Statutory U.S. federal income tax rate	35.00%	34.00%	34.00%
State income taxes, net of federal benefit	(1.30%)	(2.30%)	8.10%
State apportionment change	0.30%	23.80%	0.00%
U.S. federal rate change	(3.60%)	0.00%	0.00%
Effect of foreign operations	10.90%	7.10%	17.90%
Subpart F income	15.60%	0.00%	0.00%
Nondeductible employee compensation	2.30%	4.20%	6.90%
Loss on stock warrant liability	0.00%	0.00%	58.40%
Research tax credits	(3.40%)	0.00%	(34.70%)
Change in valuation allowance	(146.40%)	(29.30%)	(182.20%)
Sale of New Jersey tax attributes	0.00%	0.00%	50.80%
Other	0.80%	(2.50%)	11.50%
Effective tax rate	(89.80%)	35.00%	(29.30%)
Tax Deduction	99,745,000
Tax Benefit, Loss carrforwards	30,300,000
Tax Benefit, Tax credit carryforward	26,965,000	18,612,000
Deferred tax asset:
Net operating loss carry forwards	6,280,000	36,866,000
Capitalized technology license	2,519,000	2,525,000
Capitalized research expenditures	14,012,000	2,009,000
Accruals and reserves	2,172,000	1,270,000
Retirement plan	3,315,000	3,432,000
Deferred revenue	1,393,000	2,591,000
Stock-based compensation	1,389,000	1,326,000
Other	1,329,000	1,091,000
Deferred Tax Assets, Gross	59,374,000	69,722,000
Valuation allowance	(12,598,000)	(69,711,000)
Deferred tax assets	46,776,000	11,000
Deferred Tax Liabilities, Foreign Controlled Corporation	(6,070,000)	0
Period of exemption on withholding tax on royalty payments				5 years
Withholding tax rate for royalty payments		16.50%
Proceeds from sale of operating losses and tax credits			2,700,000
Deferred Tax Liabilities, Gross	(6,070,000)	0
Deferred Tax Assets, Net	40,706,000	11,000
Deferred Income Tax Expense (Benefit)	(41,418,000)	(11,000)	0
Windfalls included in net operating loss carryforwards	68,600,000	63,800,000
Valuation Allowance, Deferred Tax Asset, Change in Amount	57,100,000	4,400,000	4,500,000
Federal [Member]
Reconciliation of the statutory U.S. federal tax rate to the effective tax rate [Abstract]
Tax Deduction	79,150,000
Tax Benefit, Loss carrforwards	27,702,000
Federal [Member] | Minimum [Member]
Deferred tax asset:
Loss carry forwards, expiration date		Dec. 31, 2020
Federal [Member] | Maximum [Member]
Deferred tax asset:
Loss carry forwards, expiration date		Dec. 31, 2030
Federal [Member] | Research tax credit [Member]
Reconciliation of the statutory U.S. federal tax rate to the effective tax rate [Abstract]
Tax Benefit, Tax credit carryforward	10,360,000
Federal [Member] | Research tax credit [Member] | Minimum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2020
Federal [Member] | Research tax credit [Member] | Maximum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2031
State [Member]
Deferred tax asset:
Operating loss carryforwards sold			45,200,000
State [Member] | Minimum [Member]
Deferred tax asset:
Loss carry forwards, expiration date		Dec. 31, 2014
State [Member] | Maximum [Member]
Deferred tax asset:
Loss carry forwards, expiration date		Dec. 31, 2030
State [Member] | Research tax credit [Member]
Reconciliation of the statutory U.S. federal tax rate to the effective tax rate [Abstract]
Tax Benefit, Tax credit carryforward	2,775,000
Deferred tax asset:
Tax credit carryforwards sold			232,000
State [Member] | Research tax credit [Member] | Minimum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2020
State [Member] | Research tax credit [Member] | Maximum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2027
Foreign [Member]
Reconciliation of the statutory U.S. federal tax rate to the effective tax rate [Abstract]
Tax Deduction	20,595,000
Tax Benefit, Loss carrforwards	2,598,000
Tax Benefit, Tax credit carryforward	13,830,000
Foreign [Member] | Minimum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2020
Foreign [Member] | Maximum [Member]
Deferred tax asset:
Tax credit carryforwards, expiration date		Dec. 31, 2022
South Korea [Member]
Current income tax benefit (expense):
Foreign		(6,600,000)	(4,900,000)	(1,900,000)
UDC Ireland [Member]
Deferred tax asset:
Deferred Income Tax Expense (Benefit)	$ 6,100,000